{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:44:46Z","timestamp":1790995486913,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,8,2]],"date-time":"2014-08-02T00:00:00Z","timestamp":1406937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10067-014-2756-2","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T03:01:10Z","timestamp":1406862070000},"page":"1707-1714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients"],"prefix":"10.1007","volume":"33","author":[{"given":"Miguel","family":"Cuchacovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Aguill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Catal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,2]]},"reference":[{"key":"2756_CR1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","volume":"334","author":"F Bazzoni","year":"2000","unstructured":"Bazzoni F, Beutler B (2000) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717\u20131725","journal-title":"N Engl J Med"},{"key":"2756_CR2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","volume":"2","author":"FM Brennan","year":"1989","unstructured":"Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244\u2013247","journal-title":"Lancet"},{"key":"2756_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","volume":"223","author":"M Feldmann","year":"2008","unstructured":"Feldmann M, Maini SR (2008) Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 223:7\u201319","journal-title":"Immunol Rev"},{"key":"2756_CR4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375\u2013382","journal-title":"Lancet"},{"key":"2756_CR5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/ard.2010.148015","volume":"70","author":"P Emery","year":"2011","unstructured":"Emery P, Dorner T (2011) Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 70:2063\u20132070","journal-title":"Ann Rheum Dis"},{"key":"2756_CR6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","volume":"72","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS (2013) Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 72:64\u201371","journal-title":"Ann Rheum Dis"},{"key":"2756_CR7","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","volume":"58","author":"E Keystone","year":"2008","unstructured":"Keystone E, Heijde D, Mason D Jr, Landew\u00e9 R, Vollenhoven RV, Combe B et al (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58:3319\u20133329","journal-title":"Arthritis Rheum"},{"key":"2756_CR8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552\u20131163","journal-title":"Arthritis Rheum"},{"key":"2756_CR9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"28","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M (2004) TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 28:675\u2013681","journal-title":"Lancet"},{"key":"2756_CR10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","volume":"66","author":"GR Burmester","year":"2007","unstructured":"Burmester GR, Mariette X, Montecucco C, Monteagudo-S\u00e1ez I, Malaise M, Tzioufas AG (2007) Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 66:732\u2013739","journal-title":"Ann Rheum Dis"},{"key":"2756_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/ard.2005.035709","volume":"65","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C et al (2006) Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis 65:328\u2013334","journal-title":"Ann Rheum Dis"},{"key":"2756_CR12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","volume":"48","author":"N Vastesaeger","year":"2009","unstructured":"Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS (2009) A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 48:1114\u20131121","journal-title":"Rheumatology (Oxford)"},{"key":"2756_CR13","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381\u20133390","journal-title":"Arthritis Rheum"},{"key":"2756_CR14","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/ard.2009.121160","volume":"69","author":"K Visser","year":"2010","unstructured":"Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ et al (2010) A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 69:1333\u20131337","journal-title":"Ann Rheum Dis"},{"key":"2756_CR15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/ard.2005.035709","volume":"65","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C et al (2006) Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis 65:328\u2013334","journal-title":"Ann Rheum Dis"},{"key":"2756_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","volume":"38","author":"N Emi Aikawa","year":"2010","unstructured":"Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonf\u00e1 EN (2010) Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38:82\u201389","journal-title":"Clin Rev Allergy Immunol"},{"key":"2756_CR17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar3147","volume":"12","author":"CL Krieckaert","year":"2010","unstructured":"Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ (2010) The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 12:217","journal-title":"Arthritis Res Ther"},{"key":"2756_CR18","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L et al (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"key":"2756_CR19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/03009740410005863","volume":"33","author":"M Cuchacovich","year":"2004","unstructured":"Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H et al (2004) Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 33:228\u2013232","journal-title":"Scand J Rheumatol"},{"key":"2756_CR20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/03009740600904284","volume":"35","author":"M Cuchacovich","year":"2006","unstructured":"Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D et al (2006) Tumour necrosis factor (TNF)alpha -308\u00a0G\/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 35:435\u2013440","journal-title":"Scand J Rheumatol"},{"key":"2756_CR21","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/ar1465","volume":"7","author":"H Marotte","year":"2005","unstructured":"Marotte H, Maslinski W, Miossec P (2005) Circulating tumour necrosis factor-\u03b1 bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 7:R149\u2013R155","journal-title":"Arthritis Res Ther"},{"key":"2756_CR22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/art.23430","volume":"58","author":"H Marotte","year":"2008","unstructured":"Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P (2008) Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 58:1258\u20131263","journal-title":"Arthritis Rheum"},{"key":"2756_CR23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","volume":"67","author":"CA Wijbrandts","year":"2008","unstructured":"Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H et al (2008) The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor \u03b1 expression in the synovium. Ann Rheum Dis 67:1139\u20131144","journal-title":"Ann Rheum Dis"},{"key":"2756_CR24","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/rheumatology\/ken261","volume":"47","author":"MH Buch","year":"2008","unstructured":"Buch MH, Reece RJ, Quinn MA, English A, Cunnane G, Henshaw K et al (2008) The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology 47:1469\u20131475","journal-title":"Rheumatology"},{"key":"2756_CR25","first-page":"75","volume":"215","author":"N Braun","year":"1996","unstructured":"Braun N, Michel U, Ernst B, Metzner R, Bitsch A, Weber F et al (1996) Gene polymorphism at position -308 of the tumor-necrosis-factor alpha (TNF-alpha) in multiple sclerosis and it\u2019s influence on the regulation of TNF-alpha production. Neurosci Lett 215:75\u201378","journal-title":"Neurosci Lett"},{"key":"2756_CR26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/ajrccm.163.2.2002062","volume":"163","author":"B Schaaf","year":"2001","unstructured":"Schaaf B, Seitzer U, Pravica V, Aries S, Zabel P (2001) Tumor necrosis factor alpha promoter gene polymorphism and increased tumor necrosis factor serum bioactivity in farmer\u2019s lung patients. Am J Respir Crit Care Med 163:379\u2013382","journal-title":"Am J Respir Crit Care Med"},{"key":"2756_CR27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/art.11168","volume":"48","author":"B Mugnier","year":"2003","unstructured":"Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D (2003) Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 48:1849\u20131852","journal-title":"Arthritis Rheum"},{"key":"2756_CR28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/ard.2004.028167","volume":"64","author":"JE Fonseca","year":"2005","unstructured":"Fonseca JE, Carvalho T, Cruz M, Nero P, Sobral M, Mour\u00e3o AF et al (2005) Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 64:793\u2013794","journal-title":"Ann Rheum Dis"},{"key":"2756_CR29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","volume":"46","author":"M Seitz","year":"2007","unstructured":"Seitz M, Wirthmuller U, Moller B, Villiger PM (2007) The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46:93\u201396","journal-title":"Rheumatology (Oxford)"},{"key":"2756_CR30","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/art.23092","volume":"57","author":"S Guis","year":"2007","unstructured":"Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D et al (2007) Influence of -308 A\/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 57:1426\u20131430","journal-title":"Arthritis Rheum"},{"key":"2756_CR31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","volume":"68","author":"C Potter","year":"2009","unstructured":"Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP et al (2009) Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68:69\u201374","journal-title":"Ann Rheum Dis"},{"key":"2756_CR32","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/hmg\/ddn245","volume":"17","author":"JR Maxwell","year":"2008","unstructured":"Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J et al (2008) Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 17:3532\u20133538","journal-title":"Hum Mol Genet"},{"key":"2756_CR33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/ard.2007.074104","volume":"67","author":"C Miceli-Richard","year":"2008","unstructured":"Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P et al (2008) A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 67:478\u2013484","journal-title":"Ann Rheum Dis"},{"key":"2756_CR34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3899\/jrheum.090707","volume":"37","author":"YH Lee","year":"2010","unstructured":"Lee YH, Ji JD, Bae SC, Song GG (2010) Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238\u00a0G\/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 37:740\u2013746","journal-title":"J Rheumatol"},{"key":"2756_CR35","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/ard.2009.117622","volume":"69","author":"S Pavy","year":"2010","unstructured":"Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA et al (2010) TNF alpha \u2013308G\u2009>\u2009A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 69:1022\u20131028","journal-title":"Ann Rheum Dis"},{"key":"2756_CR36","first-page":"19","volume":"54","author":"M Fabris","year":"2002","unstructured":"Fabris M, Di Poi E, Sacco S, Damante G, Sinigaglia L, Ferraccioli G (2002) TNF- alpha gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-alpha agents: preliminary results. Reumatismo 54:19\u201326","journal-title":"Reumatismo"},{"key":"2756_CR37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155\u2013163","journal-title":"Arthritis Rheum"},{"key":"2756_CR38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MM Nielen","year":"2004","unstructured":"Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380\u2013386","journal-title":"Arthritis Rheum"},{"key":"2756_CR39","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6","volume":"43","author":"EJ Kroot","year":"2000","unstructured":"Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831\u20131835","journal-title":"Arthritis Rheum"},{"key":"2756_CR40","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/art.1780330816","volume":"33","author":"GS Alarcon","year":"1990","unstructured":"Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ (1990) Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 33:1156\u20131161","journal-title":"Arthritis Rheum"},{"key":"2756_CR41","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2006.060608","volume":"66","author":"F Bobbio-Pallavicini","year":"2007","unstructured":"Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, Montecucco C (2007) High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 66:302\u2013307","journal-title":"Ann Rheum Dis"},{"key":"2756_CR42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/ard.2004.023523","volume":"64","author":"L Rycke De","year":"2005","unstructured":"De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM et al (2005) Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64:299\u2013302","journal-title":"Ann Rheum Dis"},{"key":"2756_CR43","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/s10165-010-0305-7","volume":"20","author":"S Onishi","year":"2010","unstructured":"Onishi S, Yoshio T, Nagashima T, Minota S (2010) Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-\u03b1. Mod Rheumatol 20:528\u2013530","journal-title":"Mod Rheumatol"},{"key":"2756_CR44","doi-asserted-by":"crossref","first-page":"e89442","DOI":"10.1371\/journal.pone.0089442","volume":"9","author":"Q Lv","year":"2014","unstructured":"Lv Q, Yin Y, Li X, Shan G, Wu X, Liang D, Li Y et al (2014) The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFalpha agent treatment in patients with rheumatoid arthritis: A Meta-Analysis. PLoS ONE 9:e89442","journal-title":"PLoS ONE"},{"key":"2756_CR45","first-page":"1067","volume":"26","author":"M Cuchacovich","year":"2008","unstructured":"Cuchacovich M, Catalan D, Wainstein E, Gatica H, Soto L, Aravena O et al (2008) Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol 26:1067\u20131073","journal-title":"Clin Exp Rheumatol"},{"key":"2756_CR46","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2003.014647","volume":"63","author":"C Alessandri","year":"2004","unstructured":"Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A et al (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218\u20131221","journal-title":"Ann Rheum Dis"},{"key":"2756_CR47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/ard.2005.038851","volume":"65","author":"HA Chen","year":"2006","unstructured":"Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35\u201339","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2756_CR48","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar1851","volume":"8","author":"F Atzeni","year":"2006","unstructured":"Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C et al (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8(1):R3","journal-title":"Arthritis Res Ther"},{"key":"2756_CR49","first-page":"1972","volume":"35","author":"WH Bos","year":"2008","unstructured":"Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D et al (2008) Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 35:1972\u20131977","journal-title":"J Rheumatol"},{"key":"2756_CR50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10067-011-1679-4","volume":"30","author":"L Soto","year":"2011","unstructured":"Soto L, Sabugo F, Catalan D, Wurmann P, Cermenatti T, Gatica H et al (2011) The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) \u03b1-308\u00a0G\/G promoter polymorphism. Clin Rheumatol 30:391\u2013395","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2756-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2756-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2756-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T08:42:57Z","timestamp":1565685777000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2756-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,2]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2756"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2756-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,2]]}}}